A Novel Diagnostic Test for Irritable Bowel Syndrome

描述（由申请人提供）：肠易激综合征（IBS）是一种改变生活的肠道疾病，影响约20%的一般人群。没有单一的诊断测试阳性确认IBS。医生在诊断IBS时遵循一个协议，该协议使用标准的内窥镜检查来排除结构或生化异常，体格检查和症状问卷调查。这一低效的过程导致医疗资源的大量使用，估计每年有350万次办公室访问和220万次处方，直接和间接成本为290亿美元。 我们的目标是开发一种易于使用，低成本的呼气测试来诊断IBS。代谢解决方案（MSI）开发的测试是基于IBS患者吸收果糖不良的原理。在初步研究中，MSI展示了一种新技术，使用碳13示踪剂和未标记的果糖来识别患有IBS的个体，通过他们是否可以吸收所给予的果糖。这是第一个直接从小肠检测果糖吸收不良并将其与LBS诊断相关联的测试。 拟议的测试将大大减少国家医疗保健支出，因为正确的诊断将导致更少的办公室访问，更谨慎地使用药物和更好的一般健康和福祉的大量美国人。

DESCRIPTION (provided by applicant): Irritable Bowel Syndrome (IBS) is a life altering disorder of the intestines that effects approximately 20 percent of the general population. There is no single diagnostic test for positive confirmation of IBS. Physicians arrive at an lBS diagnosis following a protocol that uses standard endoscopic tests to exclude structural or biochemical abnormalities, a physical examination and a symptom questionnaire. This inefficient process leads to an enormous use of healthcare resources estimated at 3.5 million office visits and 2.2 million prescriptions at a direct and indirect cost of $29 billion annually. Our objective is to develop an easy to use, low cost breath test to diagnosis lBS. The test developed by Metabolic Solutions (MSI) is based on the principle that lBS patients malabsorb fructose. In preliminary studies MSI has demonstrated a novel technology using a carbon 13 tracer and unlabeled fructose to identify individuals with lBS by whether or not they can absorb the administered fructose. This is the first test to assay fructose malabsorption directly from the small intestine and correlate it to the diagnosis of LBS. The proposed test will significantly reduce national health care expenditures because proper diagnosis will lead to fewer office visits, more prudent use of drugs and better general health and well-being for a large number of Americans.